AI Stock Analysis - Bioventus (BVS)
Analysis generated March 13, 2026.
Bioventus Inc. is a medical device company that focuses on the development and commercialization of orthobiologic products that assist in the healing and restoration of the human body. Targeting musculoskeletal conditions, the company offers a wide array of solutions including bone graft substitutes, joint preservation products, and osteoarthritis care. With a commitment to innovation and diverse product portfolio, Bioventus aims to cater to the healthcare sector's growing demands. Recently, an uptick in open job positions indicates efforts toward expansion, signifying a growth-oriented outlook.
Stock Alerts - Bioventus (BVS)
 |
Bioventus | March 14 Insider Alert: McMurry-Heath Michelle is selling shares |
|
Bioventus | March 6 Price is down by -6% in the last 24h. |
|
Bioventus | March 5 Price is up by 6.3% in the last 24h. |
|
Bioventus | January 8 Price is up by 6.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Bioventus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 68 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 691 | Sign up | Sign up | Sign up |
| Instagram Followers | 781 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 432 | Sign up | Sign up | Sign up |
| X Followers | 1,846 | Sign up | Sign up | Sign up |
| X Mentions | 6 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 26,400 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,135 | Sign up | Sign up | Sign up |
About Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body’s natural healing process in the United States and internationally.
| Price | $8.87 |
| Target Price | Sign up |
| Volume | 416,034 |
| Market Cap | $581M |
| Year Range | $6.14 - $9.1 |
| Dividend Yield | 0% |
| PE Ratio | 26.12 |
| Analyst Rating | 67% buy |
| Industry | Medical Devices |
In the news
Bioventus Inc. Q4 2025 Earnings Call SummaryMarch 5 - Yahoo Entertainment |
|
Bioventus Announces Fourth Quarter and Full Year 2025 Financial ResultsMarch 5 - GlobeNewswire |
|
Barrington Research Initiates Coverage On Bioventus with Outperform Rating, Announces Price Target of $13February 8 - Benzinga |
|
 |
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 14 - SeekingAlpha |
|
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 13 - SeekingAlpha |
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 139M | 46M | 93M | 3.2M | 22M | 0.150 |
| Q2 '25 | 148M | 46M | 102M | 7.5M | 30M | 0.210 |
| Q1 '25 | 124M | 41M | 83M | -2.6M | 16M | -0.040 |
| Q4 '24 | 154M | 51M | 103M | -160,000 | 22M | 0.150 |
| Q3 '24 | 139M | 45M | 94M | -4.8M | 17M | 0.060 |
Insider Transactions View All
| McMurry-Heath Michelle filed to sell 44,997 shares at $8.8. March 13 '26 |
| NOHRA GUY P filed to sell 116,610 shares at $7.6. December 8 '25 |
| McMurry-Heath Michelle filed to sell 56,997 shares at $7.4. November 10 '25 |
| CHURCH KATRINA J filed to sell 55,557 shares at $7.6. April 15 '25 |
| D'Adamio Anthony filed to sell 131,416 shares at $7.6. April 15 '25 |
Similar companies
Read more about Bioventus (BVS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Bioventus
The Market Cap of Bioventus is $581M.
As of today, Bioventus' PE (Price to Earnings) ratio is 26.12.
Currently, the price of one share of Bioventus stock is $8.87.
The BVS stock price chart above provides a comprehensive visual representation of Bioventus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bioventus shares. Our platform offers an up-to-date BVS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Bioventus (BVS) does not offer dividends to its shareholders. Investors interested in Bioventus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Bioventus are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
